Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy

NCT02068443 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

374

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Alogliptin
DRUG: Metformin hydrochloride
DRUG: Metformin hydrochloride Placebo

Sponsor

Takeda